Review of the animal pharmacology and pharmacokinetics of fluvoxamine.
1 Fluvoxamine maleate is a compound from the series of 2-aminoethyloximethers of aralkylketones which possesses marked inhibition effects on 5-hydroxytryptamine (5-HT) uptake by blood platelets and brain synaptosomes. In contrast, it has no effect on noradrenaline uptake processes. 2 Fluvoxamine is completely absorbed in rats and dogs; the main metabolic path was similar in rat, dog, hamster, mouse and rabbit. The metabolites of fluvoxamine are inactive with regard to aminergic uptake processes. 3 Fluvoxamine is neither sedative nor stimulating, shows a very low cardiotoxic effect and no affinity for the cholinergic receptor. On the basis of the pharmacological profile, a highly favourable therapeutic ratio of antidepressant effects vs disturbing side-effects is predicted.
D000818:Animals; D000928:Antidepressive Agents / Q000378:metabolism / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D001679:Biogenic Amines / Q000378:metabolism; D016666:Fluvoxamine; D007700:Kinetics; D009474:Neurons / Q000378:metabolism; D010091:Oximes / Q000378:metabolism / Q000494:pharmacology*; D010276:Parasympatholytics; D012701:Serotonin / Q000378:metabolism
D000928:Antidepressive Agents; D001679:Biogenic Amines; D010091:Oximes; D010276:Parasympatholytics; D012701:Serotonin; D016666:Fluvoxamine